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2013WHO guidelines recommend starting ART at CD4+ T-cell counts500 cells/μL. We
present the T-cell counts from adult Africans with HIV shortly following transmission to their
sexual partners.
Methods
HIV-discordant couples in Zambia, Uganda and Rwanda were followed prospectively and
received couples counseling and condoms. HIV uninfected partners were tested for HIV at
least quarterly and HIV-infected partners received HIV care and referral for ART per
national guidelines. Upon diagnosis of incident HIV infection in the previously HIV-unin-
fected partner, a blood sample was collected from both partners to measure CD4+ T-cells
and perform viral linkage. The estimated date of infection (EDI) of the incident case was cal-
culated based on testing history. EDI was unknown for suspected transmitting partners.
Results
From 2006–2011, 4,705 HIV-discordant couples were enrolled in this cohort, and 443
cases of incident HIV infection were documented. Virus linkage analysis was performed in
374 transmission pairs, and 273 (73%) transmissions were linked genetically. CD4 counts
in the transmitting partner were measured a median of 56 days after EDI (mean:90.5,
min:10, max:396). The median CD4 count was 339 cells/μl (mean:386.4, min:15,
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Conclusions
In our cohort of discordant couples, 73% of HIV transmissions occurred within the relation-
ship, and the transmitter CD4+ T cell count shortly after the transmission event was fre-
quently higher than the WHO 2013 ART-initiation guidelines.
Introduction
Approximately 69 percent of people living with HIV reside in sub-Saharan Africa (SSA), a
region which continues to experience the highest HIV-1 incidence worldwide[1]. While 70 per-
cent of all new HIV infections in 2010 were identified in SSA (accounting for 1.9 million new
infections), increased access to antiretroviral therapy (ART) has played a role in decreasing the
number of new infections and AIDS-related deaths in the region. HIV-1 replication is effec-
tively suppressed in both blood and genital secretions when ART is taken, which decreases the
likelihood of transmitting the virus to an uninfected partner [2–6]. In recent years, the correla-
tion between ART use and the reduction of HIV-1 transmission has been strengthened by the
results of a large clinical trial, modeling studies, and observational studies. A prospective cohort
study of 3381 African heterosexual discordant couples provided evidence that ART signifi-
cantly reduced the frequency of HIV-1 transmission events between partners[7]. HPTN 052
tested this hypothesis in a clinical trial, and found a dramatic reduction of HIV transmission
among HIV-discordant couples where infected partners received ART [8]. Results from these
and other large-scale clinical research provide strong evidence that the use of ART can signifi-
cantly reduce the risk of onward HIV transmission [9–11].
The timing of ART initiation has significant implications for discordant heterosexual cou-
ples, who continue to be at very high risk of HIV infection in SSA [12, 13]. The latest update
(June 2013) of the WHO guidelines on ART initiation recommends starting ART at a CD4+ T
cell count (CD4 count) threshold of 500 cells/μL, an increase from the previous 2010 guidelines
which advised initiating treatment at a threshold of 350 cells/μL [14]. The new guidelines also
recommend initiating ART for persons in an HIV-discordant relationship regardless of CD4
count, and are predicted to expand the eligibility for ART initiation to an estimated 25.9 mil-
lion people. This expansion, if achieved, could avert potentially 3 million AIDS-related deaths
and prevent 3.5 million new HIV infections between 2013 and 2025. While the projected health
gains appear to be significant, others in the field favor a universal coverage approach, or the
“Test and Treat” strategy, which advocates the application of ART for all HIV-1 infected indi-
viduals regardless of CD4 counts [9]. The provision of ART at the level recommended by the
WHO guidelines or via “Test and Treat” has important financial and logistical implications,
especially in resource-poor settings.
The updated WHO guidelines propose covering an increasing proportion of persons with
HIV which in turn will impact the onward transmission of HIV. However, without an under-
standing of the transmitter CD4 count at the time of transmission, it is challenging to estimate
the proportion of transmission events that might be prevented by these new guidelines. Since
2006, IAVI has supported a cohort of consecutively identified volunteers with incident HIV
infection from large HIV incidence, vaccine trial preparedness studies. This study presents the
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CD4 counts of genetically linked HIV-1 transmitters shortly after the time of transmission in
an African cohort of HIV-1 discordant couples
Methods
Study population and clinical procedures
A prospective, multi-center cohort study enrolled and followed HIV discordant couples at 5
clinical research centers (CRC) in Rwanda (Projet San Francisco, Kigali), Uganda (Medical
Research Council/Uganda Virus Research Institute, Masaka and Entebbe), and Zambia (Zam-
bia-Emory HIV Research Project, Lusaka, Ndola, and Kitwe) to estimate HIV incidence and to
describe predictors of seroconversion in the HIV-uninfected partner [15]. Volunteers were
identified as HIV discordant in study clinic supported couples voluntary counseling and testing
(CVCT), or were referred from government sponsored CVCT clinics; the majority of positive
partners were newly diagnosed, no additional details on the duration of their infection was
available.
At enrollment, both partners in the couple underwent a complete physical examination and
a detailed medical history including onset of HIV-related illness and report of antiretroviral
therapy (ART) if any, and a urine pregnancy test (female partner). Follow up was monthly or
quarterly for HIV testing, risk reduction counseling, condoms, interim medical history and
symptoms-directed physical examination as needed. Acute medical care at the study clinic or a
referral slip for care and treatment at the nearby government clinic were provided as needed.
Non-HIV STIs were managed syndromically or treated per national guidelines. If HIV care,
including ART, was available near the CRC, study participants (both incident cases and sus-
pected transmitting partners) were referred as needed per national ART initiation guidelines.
Otherwise, HIV care, including ART, was provided by the CRC. These cohorts represent in
part larger efforts to characterize cohorts that might be suitable for future HIV prevention trials
[15]. As such, with the exception of initial work in Masaka, ART use in the HIV+ partner was a
criterion for exclusion from the prospective incidence cohorts.
Laboratory procedures
HIV testing included two rapid tests (Determine [Abbott Laboratories] and Unigold [Trinity
Biotech], typically in parallel, and a p24 ELISA. Discrepant rapid test results were confirmed by
a third rapid test or antibody ELISA. Upon detection of incident HIV infection, suspected
transmitting partners were invited for a single blood draw for CD4 counts, viral load and
sequencing. CD4 counts and viral load data were not available from the HIV positive partners
prior to this visit. Laboratory testing including CD4 counts and routine laboratory tests were
conducted at the CRCs; PCR [Roche Amplicor Monitor v1.5 (February 2006-January 2011) or
Abbott Real Time HIV-1 v1.0 m2000sp/m2000rt, thereafter] for viral load (lower limit of
detection: 50 copies/mL) was done at a central laboratory (CLS, Johannesburg, South Africa).
All volunteers with incident HIV infection were confirmed by PCR; their last HIV antibody-
negative sample was also tested by PCR to check for acute (i.e., Fiebig I) HIV infection at that
visit. A positive syphilis test [rapid plasma reagin, Biotec Laboratories, Inc., UK] was confirmed
by T. pallidum haemagglutination assay. Blood was collected for HIV viral load, sequencing
and subtype determination. The REGA HIV-1 subtyping tool (http://hivdb.stanford.edu/) was
used to analyze sequence from the pol gene from the first available specimen [16]. Additional
sequencing or phylogenetic analysis was done if REGA results were indeterminate [17]. Molec-
ular epidemiologic linkages were determined between volunteers with incident HIV infection
and their suspected transmitting partner by sequence comparison of pol, gag, gp120, gp41,
and/or long terminal repeat regions [18].
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Data and statistical analyses
Data analyses were conducted using STATA version 13 (Stata Corporation, College Station,
Texas, USA). Data are presented as frequencies with percentages and 95% confidence intervals
(CI). The estimated date of HIV infection (EDI) of the volunteer with incident infection was
defined as either 1) the midpoint between the last negative and first positive HIV-antibody test,
2) 14 days before the first positive p24 antigen test in the absence of a positive antibody test, 3)
10 days before the first detectable viral load (VL) test in the absence of detectable p24 antigen
or HIV antibodies, or 4) the date of a high-risk exposure event (i.e., a single, inter-visit report
of sex without a condom, or condom breakage). All HIV-1 infection was confirmed by VL test-
ing. The transmitting partner EDI was unknown; in this report EDI always refers to the esti-
mated date of the transmission event between the transmitting partner and the volunteer with
incident infection.
As CD4 counts tend to drop with time, we present the CD4 T cell data of linked partners in
the entire cohort, and in that subset with data available within the 90 days of the EDI. The chi
squared test or the Wilcoxon rank sum test are used to compare the proportion of epidemio-
logically linked transmission events and the subset of volunteers within 90 days of EDI by
demographic characteristics. We used data on CD4+ T cell decline in African adults (at a low
and high rate of 20 and 35 cells/year[19–21]) to estimate the transmitters’ CD4+ T cell counts
at the time of transmission for both the subset with data within 90 days of EDI, and all
transmitters.
Ethics statement
All participants provided informed consent. Consent was documented; either by the volun-
teer’s signature or by his or her “mark” and the signature of an impartial witness if the volun-
teer was illiterate. This study was approved by: the Rwanda National Ethics Committee, the
Uganda Virus Research Institute Science and Ethics Committee, the Uganda National Council
of Science and Technology, the University of Zambia Research Ethics Committee, and the
Emory University Institutional Review Board.
Results
Study Population
Between February 2006 and November 2011, 4,705 HIV discordant couples were enrolled and
followed monthly or quarterly at five clinical research centers in Eastern and Southern Africa.
During this period, 443 cases of incident HIV infection were documented, 241 (54%) in men
and 202 (46%) in women. The HIV incidence rate ranged from 2.1 in Entebbe, to 10.8 per 100
person-years in Ndola (Table 1). Viral linkage analysis was performed in 374 (84%) couples,
and 273 (73%) HIV transmissions were linked; this did not vary significantly by clinical
research center (p = 0.09, Table 2). There were no statistically significant differences in sex, age,
or level of education between linked and unlinked transmitting partners. Of those with linkage
evaluated, 364 (97%) were married, 19 of whom were in a polygamous relationship. Marital
status was significantly associated with viral linkage, with a greater proportion of monog-
amously married couples found to be linked (p = 0.01). We observed no statistically significant
associations of demographic characteristics in linked transmitters with CD4 T cell data prior to
90 days post EDI compared to those with data>90 days post EDI (data not shown).
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CD4+ T cell count in the transmitting partner
CD4 counts in the 273 linked transmitting partners were measured soon after the transmission
event was documented (1/273 (<1%) linked partners did not have CD4+ T cell data). The
median CD4 count was 339 cells/μl (mean: 386.4, min: 15 max: 1,434) and 134 of the 272 trans-
mitting partners (49%; 95% CI: 43, 55) had CD4 counts above 350, whereas 69 (25%; 95% CI:
21, 31) had CD4 counts above 500 (Table 3). Considering that the time interval from the EDI
to CD4 cell measurement ranged from 10 to 396 days (median: 53, mean: 86.6), and assuming
an annual decline in African adults at 20–35 cells/year [19–21], we estimated the median CD4
count at the time of transmission at 350–356 cells/μl, and the percent of transmitting partners
with CD4 counts above 500 at 26% (71 vs. 72 transmitters above 500 cells, respectively).
CD4 counts tended to be lower as the number of days post EDI increased (Fig 1): the
median CD4 counts among 193 linked partners enrolled during the first 90 days post EDI was
382 (mean: 420.3, range: 34–1,218) compared to 282 (303.7, 15–1,434) among those enrolled
after 90 days (p = 0.0001). If we consider only the 193 partners who were enrolled during the
first 90 days after the EDI, the number of transmitting partners with CD4 counts above 350
cells/μl was 110 (57%, 95% CI: 50, 64), and that of partners with CD4 counts above 500 cells/μl
was 60 (31%, 95% CI: 25, 38). Using data from this group, our estimate of CD4 counts increases
to a median of 385–386 cells at the time of transmission, with the percent above 500 cells at
32% regardless of the estimate for decline used (61 vs 62 transmitters above 500 cells,
respectively).
Viral load and reported ART use at EDI and enrollment
Viral load data were available from 253 (93%) of the linked transmitters, 10 of whom were
undetectable due to ART initiation. These 10 transmitters had initiated ART after the transmis-
sion event, but prior to enrollment in this study; viral linkages were done on older, archived
samples. Viral load among the 243 linked transmitters with detectable values was typically
measured at the same visit as the CD4 counts; the median viral load was 69,500 copies/mL
(IQR: 17,900–196,000, range: 208–8,520,000). Linked transmitters with CD4 counts of 500 and
below had significantly higher median viral load values than those with higher CD4 counts
(102,500 copies/mL [Interquartile range: 28,750–216,000] vs. 17,800 copies/mL [IQR: 6,767–
79,900] respectively, p<0.001). This relationship was similar among transmitters presenting
with CD4 counts at or below 350 cells/μl also having higher median viral loads compared to
Table 1. HIV incidence and sex at each study site.
Study site Enrolled couples Female (%) HIV incidence rate*
Kigali, Rwanda 1230 590 (48.0) 3.1 (2.5–3.6)
Masaka, Uganda 976 352 (36.1) 3.7 (2.8–4.6)
Entebbe, Uganda 598 322 (53.8) 2.1 (1.1–3.1)
Lusaka, Zambia 1150 522 (45.4) M to F: 8.9 (7.8–10.0)
F to M: 6.7 (5.9–7.7)
Ndola, Zambia 751 399 (53.1) M to F: 10.8 (7.8–14.5)
F to M: 6.1 (4.2–8.5)
Total 4705 2185 (46.4) Range: 2.1–10.8
*Cases per 100 person-years (95% CI). Stratiﬁed by sex only when the difference was statistically signiﬁcant (p<0.05)
For more details, see [15]
doi:10.1371/journal.pone.0134438.t001
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those with higher counts (115,000 copies/mL [IQR: 38,700–275,000] vs. 41,865 [IQR: 8,930–
125,000], respectively, p<0.001).
ART was typically an exclusion criterion for discordant couples in the incidence cohorts,
except from 2006–2009 in Masaka, Uganda. Once an HIV+ partner went on ART (including
after 2009 in Masaka), the couple was taken off study at a subsequent visit, however due to
reporting delays this was not always at the visit immediately following ART initiation. Of the
399 transmitting partners enrolled, 11 (3%) reported ART use starting an average of 170 days
(median; mean: 216, min: 25, max: 855) prior to the recipient’s EDI. Sequencing was not possi-
ble in the majority (6) of these volunteers due to viral suppression; however in the remaining 5,
only 1 (20%) transmission was linked to their partner (p = 0.007, Table 2). This partner started
Table 2. Demographic characteristics of the suspected transmitting partners of incident cases reported to be in HIV discordant couple
relationships.
Linkage status
Transmitting partner characteristic Total Linked % Unlinked % p value ▪
Total 374 273 73.0 101 27.0
Sex
Male 164 124 75.6 40 24.4 0.31
Female 210 149 71.0 61 29.0
Clinical Research Center
Kigali 95 75 79.0 20 21.0 0.09
Masaka 63 42 66.7 21 33.3
Lusaka 133 95 71.4 38 28.6
Entebbe 12 12 100.0 0 0.0
Kitwe & Ndola 71 49 69.0 22 31.0
On ART (self report) at EDI**
Yes 5° 1 20.0 4 80.0 0.007
No 369 272 73.7 97 26.3
Age at enrollment
Median 32 32 32 0.88
Mean 33.0 33.0 33.0
IQR 27–37 27–37 27–37
Marital status
Single 4 1 25.0 3 75.0 0.01
Previously married▪▪ 6 4 66.7 2 33.3
Married, monogamous 341 256 75.1 85 24.9
Married, polygamous 23 12 52.2 11 47.8
Educational achievement at enrollment
None 42 31 73.8 11 26.2 0.80
Some primary 231 168 72.7 63 27.3
Some secondary 88 63 71.6 25 28.4
More than secondary 13 11 84.6 2 15.4
* Data or sample not available from one or both volunteers
** Transmitting partner reports use of antiretroviral therapy, EDI: Estimated date of infection in the incident case
°An additional 6 volunteers reported being on ART at or around the time of the transmission event, however their viral load was too low to sequence for
linkage analysis
▪ Comparing linked vs. unlinked across volunteer characteristic
▪▪ Divorced, separated or widowed
doi:10.1371/journal.pone.0134438.t002
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ART 225 days before the EDI, and appeared to be failing treatment with a VL of 489,000 c/mL
24 days after the EDI.
Discussion
In this study of HIV transmission among African HIV discordant couples, we present data on
CD4 counts in the chronically infected partners shortly after they transmit the virus to their
sexual partner. The findings from the study suggest that, close to the time of transmission,
more than 50% of the transmitting partners have a CD4 count of>350 cells/μl, and approxi-
mately one third have a CD4 count of>500 cells/μl, despite the fact that these transmitters
with higher CD4 counts also tended to have lower viral loads. Similar results were found in the
Partners in Prevention HSV/HIV Transmission Study, in which 51% of transmitting partners
had a CD4 count of>350 cells/μl, and 28% had a CD4 count of>500 cells/μl (7).
The 2013 WHO guidelines on the use of ART for HIV treatment and prevention recom-
mend initiating ART at a CD4 threshold of 500 or fewer cells/μL, with priority given to those
with CD4 counts350. The guidelines also recommend putting all HIV-infected partners
within HIV discordant couples on ART, regardless of their CD4 counts, to reduce risk of trans-
mission to the uninfected partner. The implementation of these guidelines will be challenging,
particularly in Sub-Saharan Africa, the region where the highest prevalence of HIV discordant
partnerships is found [12]. Many adults have not yet been tested for HIV and do not know
their HIV status or the HIV status of their partner. In a previous report from this cohort, we
reported that CD4+ T cell counts fall below 500 in a majority of volunteers within 9 months of
EDI [22]; given the delay between infection and diagnosis that is so common with HIV infec-
tion, these new guidelines may be functionally similar to a “test and treat” program as nearly
everyone who tests positive for HIV may be eligible for ART at the time of their diagnosis.
Financial constraints and limited health care infrastructure also limit access of people living
with HIV to care and treatment programs; in many cases, priority is given to those with
advanced HIV disease and/ or very low CD4 counts [23]. It is also important to note that as of
today, relatively few programs in Africa have adopted CVCT as standard of care for the preven-
tion of HIV transmission [24], and these services, in many cases, have only been offered in the
context of research projects [25, 26]. More financial resources will therefore be needed to
strengthen the health infrastructure, to promote CVCT services, and to procure more HIV test
kits and ART drugs.
Table 3. CD4 counts (cells/μL) in 272 linked transmitters with data shortly after transmission showing
total cohort and stratified by time since estimated date of transmission event.
N % Median Mean Range
Total 272 100 339 386.4 15–1,434
>350 cells 134 49
>500 cells 69 25
90 days* 193 100 382 420.3 34–1,218
>350 cells 110 57
>500 cells 60 31
>90 days* 79 100 282 303.7 15–1,434
>350 cells 24 30
>500 cells 9 11
*Data collected  or > 90 days post the estimated date of the transmission event
doi:10.1371/journal.pone.0134438.t003
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The acceptability of treatment initiation and high adherence to ART will be critical to pre-
vent onward transmission, particularly for those who will be requested to initiate treatment
while they perceive themselves as still healthy and have high CD4 counts. HIV infected persons
who feel healthy may be less likely to get tested. Even if tested, they may be less likely to be eligi-
ble for ART and more likely to drop out of pre-ART care [27]. Because of this, ART refusals or
treatment failure due to feeling healthy remain challenging to measure and data remain sparse.
One study conducted in Ethiopia reported on 551 persons (18%) who dropped out of a cohort
of 3,012 persons starting on ART. The authors found 48% of drop outs were due to deaths,
12% were untraceable, and among the remaining 135 who stopped ART, nearly a third (41) did
so because they perceived themselves as improved, a further 75 (56%) reported stopping as
they preferred traditional medicine to the ART [28].
Another important finding that our study reinforces is the prevalence of unlinked transmis-
sions. While the 2013 WHO Guidelines recommend initiating ART in the positive partner of a
discordant couple, our study finds that approximately one quarter of transmission events
occur outside of the established relationship. Previous studies have documented rates ranging
between 15% and 30% [18, 29, 30]. In the HPTN 052 clinical trial of ART as prevention, 28%
of transmission events were not linked to their reported sexual partner [8]; while the efficacy of
this intervention was clearly very high, the effectiveness in the real world will likely be consider-
ably lower due to these transmission events from outside the couple.
A limitation of our study includes the delay between the transmission event and measure-
ment of CD4 counts in the transmitting partners. We collected the information on CD4 count
and viral load in the suspected transmitting partners only after the transmission event was
Fig 1. First available CD4 count in 272 linked transmitting partners following HIV transmission. Vertical dashed line shows the analysis cut point
of 90 days post EDI.
doi:10.1371/journal.pone.0134438.g001
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documented, typically one to three months after the estimated date of infection (median of 58
days). It is possible that some transmitting partners observed higher than expected T cell count
drops during this interval, and also that our viral load data may not be ideal representations of
the data at the time of transmission. However, CD4 T cell decline is expected to be modest in
this interval [19–21], and there was no significant difference between the observed proportion
of partners with CD4 counts above 500 and that estimated by modeling. Additionally, our
study focuses on discordant couples, which represent one of the largest at-risk groups in Africa
[12, 13]. While we observed that approximately one third of transmission events were from a
donor with a CD4 count above 500, it’s not clear that this can be generalized to other epidemio-
logically distinct key populations such as sex workers or men who report sex with men. How-
ever, observing transmission pairs in many key populations can be considerably more
challenging.
In summary, our study shows that a significant proportion of HIV transmission occurs
above the current CD4-based eligibility guidelines while the index partner may still be healthy
and less inclined to adhere to treatment. A significant proportion of transmissions also occurs
through sex with persons other than one’s regular partner. These findings reinforce the impor-
tance of strengthening prevention of onward transmission in HIV infected individuals through
early diagnosis, treatment and linkage to care. Regular testing of couples together followed by
prompt treatment of the HIV infected partner is an efficient and workable solution to minimiz-
ing the number of persons who are unknowingly in jeopardy because their spouse is HIV
infected.
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